Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
In each of the past two years, final yearly revenue has been approximately 25% more than the contracted revenue for the year so far quoted in the Q1 trading update.
Based on that, BOOM would be on target for revs this year of approximately $69M.
Obviously there are things that could happen to boost that further, but $85M+ looks a bit of a long shot at present, based on previous years patterns.
Moving in the right direction for sure, but beating 2022 figures would take a fair bit of accelerated growth over the next nine months.
Contracted revs for year so far:
April 2022: $60.5M
April 2023: $52M
April 2024: $55M
Q1 revs:
2022: $19.5M
2023: $15.4M
2024: $17.1M
Still a way to go to reach 2022 figures but moving in the right direction.
Another mooted key catalyst for the share price / market cap passes without any positive reaction from the share price.
The company unveiled a poster with new clinical data.
Its senior officers presented on it.
The data looks good, but the market said "meh".
Disappointing.
The price action (and SP level) is almost identical to the period immediately before the January results.
All eyes are on Q1 revenue, Q1 total downloads and £ per 1,000 downloads come Monday.
The market reaction to the Q1 results was muted (probably due to the iOS update issue) but that is old news now so should not be a factor this time. I will be interested to see if we get a more positive reaction to another set of decent numbers this time around.
The SP here is rising in advance of the Q1 results, just as they did prior to the land results in January.
I expect it to continue to rise until close of business on Friday.
What happens on Monday will then depend on three pieces of data:
(1) total monthly downloads for each of Jan to March.
(2) total revenue for the quarter.
(3) revenue per 1,000 downloads.
We've had lots of positive REACH updates since the least results, but nothing on these three data sets. They are what matters. If they are positive then the rise over the rest of this week will be sustained after Monday (or possibly boosted further). If they are not so positive the SP will fall back as it did after January's results.
I made good money on this share in 2021 and again between Sept and Jan. I don't hold at present but will keep a keen eye on the results on Monday as I do think it is a very good business.
A positive update. The average monthly downloads figure was around 125million for each of Q1-3 last year, before dropping to 110.1million in Q4, presumsbly due to the Apple update.
Adding 4million through these new podcasts takes a chunk out of BOOM's Apple update related drop that all podcasters experienced.
The 15th April update is a big one. All eyes on any rebound in the download figures and in the revs per 1000 downloads figure, which was up year on year and quarter to quarter in Q4. Waiting with interest and will buy back in depending on the figures.
Looks like the market likes the funding and the focus on the magnet recycling side of the business. It seems a no brainer to focus on that side. That's where there's an opportunity to use grant funding to unlock a lot of revenue.
I was last in here in 2022 and have bought a first chunk this morning.
The company is in a great position, especially with the new EU legislation in place. It has what the EU needs and there is clear potential for its recycling operations / scale up to be funded in no small part by Government grants, given the strategic importance. Seems to have been flying under the radar for a long time, but that is bound to change.
The company is certainly, publicly, trying to do things - and be seen to do them - more professionally.
The only thing TGR needs is cash. It has everything else it needs in order to be very successful and have a MUCH higher mcap. I remember thinking it was a good buy at 80p. We are only way down here at 6p because of a lack of cash.
I do not doubt that TGR will raise the cash they need to expand further and ramp up production one way or another. It's just a question of when and how, and as others have said, I would be surprised if they raised down at this low level of SP - especially as there is an expectation of a significant VAT refund coming in shortly to tide them over in the shorter term.
It is very admirable that Poddar has sought to avoid dilution as much as he has. In this company's case though, funding really is going to be a necessary step to unlock the potential and accelerate its growth. It would help to unlock its clearly massive potential, given it is sitting on - and starting to produce from - a huge resource of something the world really needs and which is only going to become more valuable.
AVCT could and should have waited a little longer before raising money, from the point of protecting PI's investments.
Had they waited a month, they could have pushed for a higher raise price.
Previously uninvested placees (some of whom will flip their shares as soon as they get a 10-20% return) seem to have benefited from a possibly avoidably cheap entry at the expense of already PI's, who have been left under water, having at best had a chance to average down (in some cases possibly committing more money than they would like to one share).
AS also toned down the language when advertising to PI's their chance to invest in the placing, talking only on opportunities to be compete effectively with other treatment, which raised question marks, but is now back with the "Holy Grail" and "uniquely placed" chat. That looks a little unfortunate at a time when any of the new placees looking for a nice short term flip of placing shares could do with a nice wee PI-driven rise to sell into.
Bearhunt - The irony of someone who has posted more than 250 times since Nov - apparently exclusively on this one share and jumping on anyone (often quite agrressively) who deviates even slightly from your narrative - accusing anyone of being a troll is quite notable.
Anyone can look at my posting on any share over the last five years and they will find reasoned and honest posts throughout, given that I am a small PI trying to make money solely on shares going up. I first bought into BOOM in around Oct 2020 at 180p.
I have given my view that the market may react negatively if the iOS17 update has any negative impact on revs. I also stated clearly that download figures show BOOM is more resilient than its peers to the update. I read today that Avast took a $7.3M dollar hit after iOS17. I prefer to wait until after the next trading update or Q1 figures (whichever comes first) before adding here, that's all. Nobody has to take the same view and it may turn out to be an error on my part.
If it does, I won't be on her calling strangers clowns or trolls. I'll leave that nonsense to others. I remain very bullish in the medium term (by which I mean once any possible iOS-related wobbles (or confected market overreactions) are out of the way). SL stated in Jan that he expected record revs for this year. I am keen to see the next set of figures for revs to confirm that BOOM is on track for that.
Triton's figures show BOOM's download figures down about 10% as a result of the Apple iOS 17 update that reduced automatic downloading of missed episodes of podcasts.
The question is whether this will hit BOOM's Q1 revenues. Presumably, BOOM would need to increase its revenue per 1000 downloads by 10% to compensate and avoid a revenue hit.
BOOM's competitors on the Triton charts have seen much larger reductions in download numbers since iOS17. In many cases, more than 30%. There are indications that BOOM is more resilient to the change and is taking a lesser hit, which may be feeding in to BOOM's rise to number 4 in the US.
I would like to see some trading update figures from BOOM in advance of the Q1 results. There is a lot of good news about, and it's great to see BOOM trumpeting it. I am a little concerned though that Stuart last has now mentioned the iOS17 update twice in RNS's and I am cautious about adding here until I see what impact iOS17 is having on BOOM's revenue and how the market reacts to any such negative impact. It's a short-term issue, but one that I am cautious of, given how this market reacts to anything that can be spun in any way as a negative, no matter how small.
Last word on this. I made eight times more money here in 2020 than I just lost by selling my remaining shares, so there's neither anger or bitterness here. AVCT has been very good for me overall. We'll all see how it pans out and there will be no regrets either way.
Rogue--Trader, what is laughable is your quantum leap from "potential to compete effectively"(the company's current words) to "it will eventually become the standard of care", "IT WORKS and IT WILL help to cure patients and make AVCT investors a hell of a lot of money!" (your words).
That's just based on pure hope as to what you want the outcome to be.
The reality is nobody on this board yet knows the following: -
1. How much of the drug is being cleaved into tumours.
2. What range of tumours it has the potential effectively to target.
3. How many rounds of treatment will be needed to achieve the same or better efficacy as standard Dox or other rival platforms.
4. How much the required number if rounds of treatment required for better efficacy than standard Dox against any type of tumour (if achieved) will cost.
5. Whether health services / health providers will consider that cost effective, making the drug economically viable.
We won't really have a good idea of much of this until the end of Stage 2, which is some way off.
It MIGHT be fantastic. It might not.
Making statements that it is going to be the standard of care, will make investors a lot of money, and that IT WILL help cure cancer patients is simply not based on data.
Neither of us knows at this stage whether this initial drug will be approved or make it to the market.
As I no longer hold and do not intend to in the short term at least, I'll leave the chat to others now.
Jive-turkey, the switch in language from paradigm shift to potential to compete effectively with rival platforms was first used in last week's RNS's re the recent raise.
Those RNS's were aimed squarely at investors rather than the scientific community.
Your argument that the change in tone is determined by a change in audience from investors to scientific specialists doesn't stack up. The same toned down language is being used for both audiences and was directed at investors first.
That's a red flag for me, given AS's previous record of hyping AVCT's LFT's to the heavens, only for NONE to be sold.
I wish you luck olderandwiser and hope that long terms this does as well as many hope it will.
There's no emotion for me in my decision. I took the emotion out of it. I have been burned before by buying into hype that failed to crystallise and have decided not to throw more money at this particular share. Putting more money in here would mean risking a sum that I would not be comfortable with losing, that's all, against a background where as more clinical data is being gleaned behind the scenes, the CEO's rhetoric is cooling.
Yes. It was a "paradigm shift" and the "holy grail" of targeted chemo.
Now AVA6000 has the potential (i.e. a maybe) to compete with other mechanisms of targeting chemo (sorry, what competition? This was never mentioned before).
This is a huge shift in what the company is saying - and allied to the fact that they could only raise at a huge discount - is a big red flag for me. Very, very disappointing. I did not take any 50p shares, not have I bought in since the raise. I took a significant loss and, personally, would not put any more money in here. I wish good luck to all who have, but for me, I am afraid all the signs are there that the story has changed (or that the story was hyped in the first place while funding was being sought).
Ronnycant. Not a name I recognise as having been here for very long. I have been posting on the AVCT board for more than four years, when I first bought in, on the strength of pre|CISION - months BEFORE the Covid LFT's were announced.
As I said - EXISTING holders did not fully subscribe the REX offer.
Not enough existing holders were prepared to take shares in the REX offer - even at 50p - for the target sum to be raised from those holders.
(i.e. Existing holders' faith in AS and AVCT is seriously on the wane).
Who can blame them?